These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

486 related items for PubMed ID: 16869749

  • 1. The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing.
    Kaelin WG.
    Cold Spring Harb Symp Quant Biol; 2005; 70():159-66. PubMed ID: 16869749
    [Abstract] [Full Text] [Related]

  • 2. Role of VHL gene mutation in human cancer.
    Kim WY, Kaelin WG.
    J Clin Oncol; 2004 Dec 15; 22(24):4991-5004. PubMed ID: 15611513
    [Abstract] [Full Text] [Related]

  • 3. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, Maher ER.
    Cancer Res; 2002 Jul 01; 62(13):3803-11. PubMed ID: 12097293
    [Abstract] [Full Text] [Related]

  • 4. VHL mutations linked to type 2C von Hippel-Lindau disease cause extensive structural perturbations in pVHL.
    Knauth K, Cartwright E, Freund S, Bycroft M, Buchberger A.
    J Biol Chem; 2009 Apr 17; 284(16):10514-22. PubMed ID: 19228690
    [Abstract] [Full Text] [Related]

  • 5. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
    Kaelin WG.
    Clin Cancer Res; 2004 Sep 15; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
    [Abstract] [Full Text] [Related]

  • 6. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH.
    Oncogene; 2000 Nov 16; 19(48):5435-43. PubMed ID: 11114720
    [Abstract] [Full Text] [Related]

  • 7. The von Hippel-Lindau tumor suppressor gene.
    Kondo K, Kaelin WG.
    Exp Cell Res; 2001 Mar 10; 264(1):117-25. PubMed ID: 11237528
    [Abstract] [Full Text] [Related]

  • 8. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
    Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M, Kaelin WG.
    Hum Mol Genet; 2001 May 01; 10(10):1019-27. PubMed ID: 11331612
    [Abstract] [Full Text] [Related]

  • 9. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.
    Clifford SC, Cockman ME, Smallwood AC, Mole DR, Woodward ER, Maxwell PH, Ratcliffe PJ, Maher ER.
    Hum Mol Genet; 2001 May 01; 10(10):1029-38. PubMed ID: 11331613
    [Abstract] [Full Text] [Related]

  • 10. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma.
    Sufan RI, Jewett MA, Ohh M.
    Am J Physiol Renal Physiol; 2004 Jul 01; 287(1):F1-6. PubMed ID: 15180922
    [Abstract] [Full Text] [Related]

  • 11. Genotype-phenotype correlations, and retinal function and structure in von Hippel-Lindau disease.
    Wittström E, Nordling M, Andréasson S.
    Ophthalmic Genet; 2014 Jun 01; 35(2):91-106. PubMed ID: 24555745
    [Abstract] [Full Text] [Related]

  • 12. Von Hippel-Lindau disease.
    Kaelin WG.
    Annu Rev Pathol; 2007 Jun 01; 2():145-73. PubMed ID: 18039096
    [Abstract] [Full Text] [Related]

  • 13. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
    Maynard MA, Ohh M.
    Am J Nephrol; 2004 Jun 01; 24(1):1-13. PubMed ID: 14654728
    [Abstract] [Full Text] [Related]

  • 14. [Genetics and angiogenesis: the example of von Hippel-Lindau disease].
    Richard S, Ladroue C, Gad S, Giraud S, Gardie B, Réseau national maladie de VHL et prédispositions héréditaires au cancer du rein de l'Institut national du cancer (INCa).
    Bull Cancer; 2007 Jul 01; 94 Spec No():S170-9. PubMed ID: 17846002
    [Abstract] [Full Text] [Related]

  • 15. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
    Tsuchiya MI, Okuda H, Takaki Y, Baba M, Hirai S, Ohno S, Shuin T.
    Oncol Rep; 2005 Jun 01; 13(6):1033-41. PubMed ID: 15870918
    [Abstract] [Full Text] [Related]

  • 16. The HIF and other quandaries in VHL disease.
    Tarade D, Ohh M.
    Oncogene; 2018 Jan 11; 37(2):139-147. PubMed ID: 28925400
    [Abstract] [Full Text] [Related]

  • 17. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma.
    Kaelin WG.
    Clin Cancer Res; 2007 Jan 15; 13(2 Pt 2):680s-684s. PubMed ID: 17255293
    [Abstract] [Full Text] [Related]

  • 18. RSUME inhibits VHL and regulates its tumor suppressor function.
    Gerez J, Tedesco L, Bonfiglio JJ, Fuertes M, Barontini M, Silberstein S, Wu Y, Renner U, Páez-Pereda M, Holsboer F, Stalla GK, Arzt E.
    Oncogene; 2015 Sep 10; 34(37):4855-66. PubMed ID: 25500545
    [Abstract] [Full Text] [Related]

  • 19. The von hippel-lindau tumor suppressor protein: an update.
    Kaelin WG.
    Methods Enzymol; 2007 Sep 10; 435():371-83. PubMed ID: 17998064
    [Abstract] [Full Text] [Related]

  • 20. [Von-Hippel-Lindau (VHL) protein function by initiation and progression of renal cancer].
    Moch H.
    Pathologe; 2008 Nov 10; 29 Suppl 2():149-52. PubMed ID: 18751708
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.